Neurology

CureVac Announces Financial Results for the Fourth Quarter and Full-Year 2023 and Provides Business Update

Organizational redesign and rightsizing initiated across company to streamline structures, increase efficiency and reduce operating costsTogether with GSK, ended Pandemic…

2 months ago

CureVac Appoints Thaminda Ramanayake as New Chief Business Officer

Mr. Ramanayake brings more than fifteen years of experience in biopharma company development and deal-makingStrong track record of successful clinical…

2 months ago

Evotec Presents Fiscal Year 2023 Results and Announces Priority Reset to Focus on Profitable Growth

FINANCIAL RESULTS FOR 2023 FULLY MET UPDATED GUIDANCEPRIORITY RESET TO PROFITABLE GROWTH: SIZE & FOOTPRINT ADJUSTMENTS TO DRIVE EXPECTED ANNUALISED…

2 months ago

Evotec SE appoints Dr Christian Wojczewski as Chief Executive Officer

HAMBURG, GERMANY / ACCESSWIRE / April 23, 2024 / The Supervisory Board of Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX,…

2 months ago

PaxMedica Responds to Emergency Request for IV Suramin and Commits to Provide Immediate Access to PAX-101

TARRYTOWN, New York, April 23, 2024 (GLOBE NEWSWIRE) -- via IBN – PaxMedica Inc. (Nasdaq: PXMD) (the “Company”), a leading…

2 months ago

Tiziana Life Sciences Announces Additional Clinical Improvements Among Multiple Sclerosis Patients in its Expanded Access Program

70% of Patients in the Expanded Access Program (EAP) Have Seen Measurable Clinical Improvement in Their Fatigue After Six Months…

2 months ago

Tiziana Life Sciences Announces Study Results from Intranasal Anti-CD3 Foralumab in Multiple Sclerosis Patients with PIRA Highlighted in Neurology Today®

- Intranasal foralumab attenuated microglial activation in patients with non-active secondary progressive multiple sclerosis and progression independent of relapse (PIRA)…

2 months ago

Jaguar Health Appoints Biopharmaceutical Industry Veteran to Execute Company’s In-licensing Growth Strategy in the Areas of Cancer and GI Supportive Care

Catherine Miller Collis was instrumental in bringing about Jaguar's recent in-license agreement for FDA-approved Gelclair®, a protective gel for management…

2 months ago

Evotec and Variant Bio Enter Strategic Partnership to Discover and Develop Fibrosis Treatments

COLLABORATION LEVERAGES VARIANT BIO'S CUTTING-EDGE GENOMIC DISCOVERY PLATFORM AND EVOTEC'S INTEGRATED END-TO-END R&D PLATFORM AND DISEASE AREA EXPERTISE TO ADDRESS…

2 months ago

Evotec SE to Announce Results for Fiscal Year 2023 on 24 April 2024

HAMBURG, GERMANY / ACCESSWIRE / April 17, 2024 / Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ:EVO) will…

2 months ago